HEADER HYDROLASE/HYDROLASE INHIBITOR 11-NOV-13 4NJT TITLE CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 TITLE 2 PROTEASE IN COMPLEX WITH DARUNAVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B, C, D; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS MULTIDRUG-RESISTANCE, HIV-1 PROTEASE, DARUNAVIR, NON-PEPTIDIC KEYWDS 2 INHIBITOR, PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.S.YEDIDI,H.GARIMELLA,S.B.CHANG,J.D.KAUFMAN,D.DAS,P.T.WINGFIELD, AUTHOR 2 A.K.GHOSH,H.MITSUYA REVDAT 4 28-FEB-24 4NJT 1 REMARK HETSYN REVDAT 3 25-JUN-14 4NJT 1 JRNL REVDAT 2 21-MAY-14 4NJT 1 JRNL REVDAT 1 02-APR-14 4NJT 0 JRNL AUTH R.S.YEDIDI,H.GARIMELLA,M.AOKI,H.AOKI-OGATA,D.V.DESAI, JRNL AUTH 2 S.B.CHANG,D.A.DAVIS,W.S.FYVIE,J.D.KAUFMAN,D.W.SMITH,D.DAS, JRNL AUTH 3 P.T.WINGFIELD,K.MAEDA,A.K.GHOSH,H.MITSUYA JRNL TITL A CONSERVED HYDROGEN-BONDING NETWORK OF P2 JRNL TITL 2 BIS-TETRAHYDROFURAN-CONTAINING HIV-1 PROTEASE INHIBITORS JRNL TITL 3 (PIS) WITH A PROTEASE ACTIVE-SITE AMINO ACID BACKBONE AIDS JRNL TITL 4 IN THEIR ACTIVITY AGAINST PI-RESISTANT HIV. JRNL REF ANTIMICROB.AGENTS CHEMOTHER. V. 58 3679 2014 JRNL REFN ISSN 0066-4804 JRNL PMID 24752271 JRNL DOI 10.1128/AAC.00107-14 REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.8.1_1168) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 22.48 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.180 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 3 NUMBER OF REFLECTIONS : 31875 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.202 REMARK 3 R VALUE (WORKING SET) : 0.200 REMARK 3 FREE R VALUE : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.070 REMARK 3 FREE R VALUE TEST SET COUNT : 1615 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 22.4765 - 4.4515 0.99 2604 132 0.1684 0.1719 REMARK 3 2 4.4515 - 3.5378 0.99 2550 163 0.1476 0.1849 REMARK 3 3 3.5378 - 3.0919 0.99 2563 140 0.1735 0.2114 REMARK 3 4 3.0919 - 2.8098 0.99 2485 145 0.1901 0.2341 REMARK 3 5 2.8098 - 2.6087 0.99 2572 115 0.1964 0.2713 REMARK 3 6 2.6087 - 2.4551 0.99 2560 137 0.2068 0.2633 REMARK 3 7 2.4551 - 2.3323 0.99 2511 127 0.2156 0.3046 REMARK 3 8 2.3323 - 2.2308 0.98 2508 122 0.3142 0.4111 REMARK 3 9 2.2308 - 2.1450 0.99 2507 127 0.2525 0.3112 REMARK 3 10 2.1450 - 2.0711 0.98 2527 137 0.2357 0.2931 REMARK 3 11 2.0711 - 2.0063 0.99 2526 141 0.2461 0.2630 REMARK 3 12 2.0063 - 1.9500 0.93 2347 129 0.2768 0.3164 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.270 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 25.030 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.009 3206 REMARK 3 ANGLE : 1.261 4356 REMARK 3 CHIRALITY : 0.082 512 REMARK 3 PLANARITY : 0.005 546 REMARK 3 DIHEDRAL : 14.208 1222 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4NJT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 30-DEC-13. REMARK 100 THE DEPOSITION ID IS D_1000083292. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 25-SEP-12 REMARK 200 TEMPERATURE (KELVIN) : 95 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN A200 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 31996 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.950 REMARK 200 RESOLUTION RANGE LOW (A) : 28.830 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.09700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.95 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.01 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : 3.20 REMARK 200 R MERGE FOR SHELL (I) : 0.09700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 7.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: BALBES REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.06 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.57 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.0 M SODIUM CHLORIDE (PRECIPITANT), REMARK 280 0.1 M CITRIC ACID (BUFFER), PH 5.0, VAPOR DIFFUSION, HANGING REMARK 280 DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 28.80000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4890 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9300 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -33.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4870 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -33.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH B 217 O HOH B 291 1.91 REMARK 500 O HOH C 121 O HOH D 305 1.91 REMARK 500 O HOH B 226 O HOH B 317 1.92 REMARK 500 O HOH D 206 O HOH D 300 1.96 REMARK 500 O HOH A 147 O HOH A 169 2.00 REMARK 500 O HOH B 281 O HOH B 283 2.03 REMARK 500 OD1 ASP B 35 NH2 ARG B 57 2.05 REMARK 500 O HOH B 296 O HOH B 299 2.05 REMARK 500 O HOH C 147 O HOH C 152 2.08 REMARK 500 O HOH D 223 O HOH D 267 2.09 REMARK 500 O HOH D 223 O HOH D 277 2.12 REMARK 500 O HOH C 158 O HOH C 161 2.12 REMARK 500 O HOH A 178 O HOH A 183 2.14 REMARK 500 OD1 ASP B 30 O HOH B 236 2.15 REMARK 500 O HOH A 149 O HOH A 152 2.16 REMARK 500 O HOH C 113 O HOH C 117 2.16 REMARK 500 O HOH D 289 O HOH D 292 2.17 REMARK 500 O HOH B 262 O HOH B 294 2.18 REMARK 500 OE2 GLU D 21 O HOH D 228 2.18 REMARK 500 O HOH D 285 O HOH D 296 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 170 O HOH B 280 2545 1.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 017 B 101 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 017 D 101 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4NJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH TIPRANAVIR REMARK 900 RELATED ID: 4NJV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH RITONAVIR REMARK 900 RELATED ID: 4HLA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH REMARK 900 DARUNAVIR REMARK 900 RELATED ID: 4NJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL008 DBREF 4NJT A 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4NJT B 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4NJT C 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4NJT D 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 A 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 A 99 GLN LEU GLY PHE THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 B 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 B 99 GLN LEU GLY PHE THR LEU ASN PHE SEQRES 1 C 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 C 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 C 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 C 99 GLY ARG TRP LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 C 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 C 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 C 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 C 99 GLN LEU GLY PHE THR LEU ASN PHE SEQRES 1 D 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 D 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 D 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 D 99 GLY ARG TRP LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 D 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 D 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 D 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 D 99 GLN LEU GLY PHE THR LEU ASN PHE HET 017 B 101 38 HET 017 D 101 38 HETNAM 017 (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3- HETNAM 2 017 [[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2- HETNAM 3 017 HYDROXYPROPYLCARBAMATE HETSYN 017 DARUNAVIR; TMC114; UIC-94017 FORMUL 5 017 2(C27 H37 N3 O7 S) FORMUL 7 HOH *420(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 86 GLY B 94 1 9 HELIX 4 4 GLY C 86 THR C 91 1 6 HELIX 5 5 GLN C 92 GLY C 94 5 3 HELIX 6 6 GLY D 86 THR D 91 1 6 HELIX 7 7 GLN D 92 GLY D 94 5 3 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N ASN A 98 O THR B 96 SHEET 4 A 4 GLN B 2 ILE B 3 -1 O ILE B 3 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O VAL A 56 N ARG A 45 SHEET 3 B 8 HIS A 69 GLY A 78 -1 O VAL A 71 N ILE A 64 SHEET 4 B 8 THR A 31 GLU A 34 1 N THR A 31 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 ILE A 10 VAL A 15 -1 N VAL A 15 O GLN A 18 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 43 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLY B 52 N GLY B 49 SHEET 3 C 8 HIS B 69 VAL B 77 -1 O VAL B 77 N ARG B 57 SHEET 4 C 8 THR B 31 LEU B 33 1 N LEU B 33 O LEU B 76 SHEET 5 C 8 ILE B 84 ILE B 85 -1 O ILE B 84 N VAL B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 N LEU B 23 O ILE B 85 SHEET 7 C 8 ILE B 10 VAL B 15 -1 N ILE B 13 O LYS B 20 SHEET 8 C 8 GLY B 52 ILE B 66 -1 O GLU B 65 N LYS B 14 SHEET 1 D 4 GLN C 2 ILE C 3 0 SHEET 2 D 4 THR D 96 ASN D 98 -1 O LEU D 97 N ILE C 3 SHEET 3 D 4 THR C 96 ASN C 98 -1 N ASN C 98 O THR D 96 SHEET 4 D 4 GLN D 2 ILE D 3 -1 O ILE D 3 N LEU C 97 SHEET 1 E 8 TRP C 42 GLY C 49 0 SHEET 2 E 8 GLY C 52 ILE C 66 -1 O VAL C 56 N ARG C 45 SHEET 3 E 8 HIS C 69 GLY C 78 -1 O VAL C 71 N ILE C 64 SHEET 4 E 8 THR C 31 GLU C 34 1 N THR C 31 O LEU C 76 SHEET 5 E 8 ILE C 84 ILE C 85 -1 O ILE C 84 N VAL C 32 SHEET 6 E 8 GLN C 18 LEU C 24 1 N LEU C 23 O ILE C 85 SHEET 7 E 8 ILE C 10 VAL C 15 -1 N ILE C 13 O LYS C 20 SHEET 8 E 8 GLY C 52 ILE C 66 -1 O GLU C 65 N LYS C 14 SHEET 1 F 8 LYS D 43 GLY D 49 0 SHEET 2 F 8 GLY D 52 ILE D 66 -1 O GLN D 58 N LYS D 43 SHEET 3 F 8 HIS D 69 VAL D 77 -1 O VAL D 71 N ILE D 64 SHEET 4 F 8 THR D 31 LEU D 33 1 N LEU D 33 O LEU D 76 SHEET 5 F 8 ILE D 84 ILE D 85 -1 O ILE D 84 N VAL D 32 SHEET 6 F 8 LEU D 19 LEU D 24 1 N LEU D 23 O ILE D 85 SHEET 7 F 8 ILE D 10 VAL D 15 -1 N ILE D 13 O LYS D 20 SHEET 8 F 8 GLY D 52 ILE D 66 -1 O GLU D 65 N LYS D 14 SITE 1 AC1 17 ASP A 25 GLY A 27 ALA A 28 ASP A 30 SITE 2 AC1 17 GLY A 49 ILE A 50 PRO A 81 THR A 82 SITE 3 AC1 17 HOH A 118 ASP B 25 GLY B 27 ASP B 29 SITE 4 AC1 17 ASP B 30 GLY B 48 GLY B 49 ILE B 50 SITE 5 AC1 17 HOH B 223 SITE 1 AC2 20 ASP C 25 GLY C 27 ALA C 28 ASP C 30 SITE 2 AC2 20 VAL C 32 GLY C 48 GLY C 49 PRO C 81 SITE 3 AC2 20 THR C 82 ILE C 84 ASP D 25 GLY D 27 SITE 4 AC2 20 ALA D 28 ASP D 29 ASP D 30 GLY D 48 SITE 5 AC2 20 GLY D 49 ILE D 50 THR D 82 HOH D 217 CRYST1 44.950 57.600 86.480 90.00 90.02 90.00 P 1 21 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022247 0.000000 0.000008 0.00000 SCALE2 0.000000 0.017361 0.000000 0.00000 SCALE3 0.000000 0.000000 0.011563 0.00000